subject: Pharmaceutical Industry About The Current Impasse? [print this page] For all investors or shareholders and the market, industry sector index of the high and low, often fully reflect the level of development of this industry and the boom of the industry. We hope that the pharmaceutical industry has been a hot spot for investment, many financial media or publications, many times leading financial experts, stock analysts, economists and even the very famous article for the pharmaceutical industry and the bullish view, we all optimistic about Chinese medicine industry, and most ordinary shareholders and investors are confident the arrival of good news waiting for the pharmaceutical industry. However, the actual front of us but on the contrary, in recent years, the pharmaceutical industry's development and boom of "long-awaited" or did not come out, medicine plate stock index has remained at a very low "floor" level, for a long time has not reached the market and shareholders are expected.
We can trade blocks from the Shanghai stock index to a better understanding of this issue in recent years, the Shanghai index's highest point, lowest point since late April 6100 the index points, respectively, 3100 points 3300 points, medicine index plate is 2900 points, 1800 points, 2100 points, we can from this data set, see the problem. From the market and the various elements of the comprehensive economic situation, the Shanghai index represents the market and the investment boom of the average level, we could see that the pharmaceutical industry's development level and the overall market average, compared, there significant gaps; we then index and index of Medicine plate top plate common index's highest point, lowest point in the index since late April 11,000 points, 6,000 points, 6,600 points compared to the far, far, almost there is no comparability. Plate in the stock market industry, the sector index, the medical section at the bottom a long time within the last five hesitant, are among the most depressed sectors. Common sense from the horizontal and general comparisons of thinking, medicine and public sections, there are many similarities to, medicine consumption, from a broader perspective, also belong to the scope of public spending, especially in China in recent years throughout the country, from the widely carried out from urban to rural medical insurance system for the deepening of reform, the pharmaceutical industry as a proportion of the mass public consumption growing, great development opportunities for the pharmaceutical industry should come.
Plate index from the above, for most people, whether ordinary investors or investors, the financial sector master, or holding a huge amount of money in the "big brothers-level" dealer in securities, see in addition to disappointed, there are puzzling or confusing. Plate from the pharmaceutical industry throughout the technical and practical point of view, a very long period of time, the pharmaceutical industry downturn or weakness will not be significantly improved, we do not rule out the possibility of Traditional Chinese Medicine API Stocks will be out of the plight of the industry, become a sought after "dark horse." However, this is just an isolated phenomenon, not to represent the entire industry. So, yes, we have from the main components of the pharmaceutical industry and pharmaceutical industry source?? Pharmaceutical industry sub-sectors, APIs in the production and management of deep-seated problems, to talk about our common concern for the analysis we For the mysteries of the pharmaceutical industry will be very helpful to get the market from the real situation, pharmaceutical raw materials industry has entered the era of low profits.
1. Pharmaceutical prices, pressure from the international market, market downturn, increased variable
Pharmaceutical industry in China, have experienced the glory of the last century 90's period to period in which China's Pharmaceutical Industry, the successful undertaking of the United States, Japan, Switzerland, Italy, Spain and other developed countries and European countries, transfer of industries, in a short period of 10 years to realize the rapid development of China's Pharmaceutical Industry, Pharmaceutical industries in developed countries have gone through nearly 60 years to finish the way for China to become world largest producer and exporter of pharmaceutical raw materials position and laid a solid foundation. According to Chinese medicine and health products from China Chamber of Commerce statistics, China has now been able to produce more than 1500 kinds of chemical medicine, pharmaceutical raw materials for production in 2005 up to 1.23 million tons (not including chemical Intermediate And precursor drugs), some products in the international market also occupies an important role. For example, penicillin industrial salt, Vitamin C , Cephalosporin Neomycin C, so the adriamycin, erythromycin, tetracycline and other fermented primary products, pharmaceutical raw materials of chemical synthetic drugs such as caffeine, acetaminophen, aspirin, and quinolones Ketone Antibiotic Norfloxacin, ciprofloxacin, ofloxacin, enoxacin and other production also ranks first in the world.
However, over time, China's Pharmaceutical Industry in the production and management superiority, also subject to other pharmaceutical raw materials from the world's countries and regions emerging challenges, which our most powerful opponent was in India, they use the same premium Competition of the way, and we continue to price competition in the international market, after years of battle and fight after fight, China Pharmaceutical prices in the international market becoming less and less, and many varieties almost at a profitable level. Summed up China's Pharmaceutical Industry we walked the walk, then we would clearly recognize, China Pharmaceutical industry, this "golden age", "gold content" is not high, in a sense, we only simple to undertake the United States, Japan, Switzerland, Italy, Spain and other developed countries and the European countries the transfer of industries, and not too high technological content and high-tech, on the contrary, we are also developed Pharmaceutical industry pollution, waste, or also introduce a simple technique to repeat our country, we have developed a low purchase price in order to advance the bottom line capacity of the environment to absorb the cost of production of pharmaceutical raw products, pollution never left us confused. Result of China Pharmaceutical Industry in a very vulnerable position, in the event from other countries and regions, competitors, our industry advantage will be exhausted. At the same time, we face from abroad, production and operation of this new low-priced Pharmaceutical challenge, there comes from anti-dumping lawsuits in developed countries, so that we Pharmaceutical industry withstand the adverse conditions on all sides by the enemy, so we should calm down, center assessment and review of China's Pharmaceutical Industry by walk from the golden age to the present period of recession or low-profit non-trivial distance, changing the face of China's Pharmaceutical Industry and diverse international markets, should be transition time, otherwise, we can only market in the international pharmaceutical raw materials can only be maintained in the "big country" low status, and the Pharmaceutical "power" will be forever
Pharmaceutical Industry About The Current Impasse?
